BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Chemotherapy"
DOI: 10.1080/1120009x.2022.2043512
Abstract: Abstract Bendamustine plus rituximab (BR) and rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) have been shown to be effective in the treatment of indolent B-cell lymphomas (iBCL). The survival outcomes and adverse events of BR… read more here.
Keywords: meta analysis; chop; plus rituximab; indolent cell ... See more keywords
Bendamustine plus rituximab: is it a BRIGHT idea?
Sign Up to like & getrecommendations! Published in 2019 at "Chinese clinical oncology"
DOI: 10.21037/cco.2019.10.03
Abstract: Flinn et al . have reported the results of the long-term follow-up for the BRIGHT trial, an international study which compared the efficacy and the safety of bendamustine plus rituximab (BR) with either rituximab plus… read more here.
Keywords: rituximab bright; bendamustine plus; bright idea; oncology ... See more keywords
Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1120967
Abstract: In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of care for patients with symptomatic advanced disease. More recently, the combination… read more here.
Keywords: chop; first line; follicular lymphoma; bendamustine plus ... See more keywords